top of page

Company News

Kelun-Biotech to present clinical updates for SKB264 at 2023 ESMO

Selected for mini-oral presentation at 2023 ESMO: Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC)


August 10, 2023

Kelun-Biotech Successfully Listed on the Main Board of HKEX

Kelun-Biotech officially debuts with HK$13.58 billion IPO on HKEX


July 11, 2023

SKB264 (MK-2870) is approved for clinical trials in the European Union

CTA of Kelun-Biotech's TROP2-ADC (SKB264, MK-2870) in combination with pembrolizumab is approved in the European Union.


June 19, 2023

Kelun-Biotech to present recent clinical data for SKB264 (TROP2 ADC) at ASCO 2023

Kelun-Biotech will present results of Phase 2 study of SKB264 (TROP2 ADC) in metastatic NSCLC.


May 27, 2023

KLUS Pharma to attend 2023 ASCO Annual Meeting

KLUS Pharma is attending 2023 ASCO Annual Meeting in Chicago from June 2-6th


May 27, 2023

KLUS Pharma to attend the 2023 BIO International Convention

KLUS Pharma will attend the BIO International Convention in Boston, MA from June 5-8, 2023.


April 13, 2023

KLUS Pharma to attend 2023 AACR Annual Meeting

KLUS Pharma will attend the 2023 AACR Annual Meeting in Orlando, Florida from April 14-19, 2023.


April 10, 2023

KLUS Pharma is Attending 2023 BIO-Europe Spring!

KLUS Pharma will attend 2023 Bio-Europe Spring live and virtual partnering events.


March 12, 2023

Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer

Merck and Kelun-Biotech announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.


December 22, 2022

2022 SABCS | Kelun-Biotech TROP2-ADC (SKB264, MK-2870) Phase 2 Study Poster

A scientific poster of SKB264 will be presented at 2022 SABCS highlighting key data from Phase 2 TNBC study.


December 14, 2022

KLUS Pharma is Attending BIO Partnering at JPM 2023!

Come meet with us at BIO Partnering at JPM 2023 to learn more about our innovative pipeline!


November 14, 2022

KLUS Pharma is Attending BioPharm America in Boston!

KLUS Pharma is Attending BioPharm America in Boston from September 28-29


September 8, 2022

bottom of page